The long-term objective of this work is to determine the role of heparan sulfate in regulating osteolytic bone metastasis and to use this knowledge to develop novel therapies. Heparan sulfates bind to, and regulate the function of, a host of effector molecules that control cell signaling (e.g., growth factors, chemokines), including factors that regulate metastasis and osteolysis. Recent studies demonstrate that heparanase mediated cleavage of heparan sulfate enhances the biological activity of heparan sulfate by releasing fragments 10-20 sugar residues long that potentiate the activity of growth factors better than do intact heparan sulfate chains. Heparanase activity promotes angiogenesis and metastasis in some tumors and elevated expression of heparanase is associated with a poor prognosis in some types of cancer. However, the role of heparanase in osteolytic metastasis is wholly unknown. We have made several striking discoveries supporting the hypothesis that elevated expression of heparanase in multiple myeloma and breast cancer promotes osteolytic bone metastasis. Our immediate goal is to test this hypothesis by enhancing heparanase expression in tumor cells and testing their growth, metastatic and osteolytic behavior in animal models including a new model in which cells with elevated heparanase spontaneously metastasize from subcutaneous sites to bone. This goal will be accomplished by execution of three specific aims using both myeloma and breast cancer cells.
Aim 1 : Animal models of both spontaneous and experimental metastasis will be used to determine the effect of elevated heparanase expression on metastasis to bone.
Aim 2 : Tumor cells will be directly injected into bone and the effect of elevated heparanase expression on the growth of tumor within the bone and on bone turnover will be analyzed. In addition, the mechanism of heparanase action will be examined both in vivo and in vitro, including examining the effect of heparanase activity on osteoclast-stimulating factors.
Aim 3 : Inhibitors of heparanase will be tested in the animal models to examine the potential therapeutic effects of these compounds and to confirm the role of heparanase in osteolytic metastasis. This work will provide a comprehensive understanding of how heparanase and degradation of heparan sulfate regulates osteolytic bone metastasis and holds potential for discovery of new therapeutic targets for controlling tumors within bone.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA103054-06
Application #
7281610
Study Section
Special Emphasis Panel (ZCA1-SRRB-U (M2))
Program Officer
Mohla, Suresh
Project Start
2003-09-01
Project End
2009-06-30
Budget Start
2007-07-01
Budget End
2009-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$304,164
Indirect Cost
Name
University of Alabama Birmingham
Department
Pathology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Kelly, Thomas; Suva, Larry J; Nicks, Kristy M et al. (2010) Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. J Bone Miner Res 25:1295-304
Purushothaman, Anurag; Uyama, Toru; Kobayashi, Fumi et al. (2010) Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115:2449-57
Chen, Ligong; Sanderson, Ralph D (2009) Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One 4:e4947
Purushothaman, Anurag; Chen, Ligong; Yang, Yang et al. (2008) Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283:32628-36
Casu, Benito; Vlodavsky, Israel; Sanderson, Ralph D (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36:195-203
Sanderson, Ralph D; Yang, Yang (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 25:149-59
Yang, Yang; Macleod, Veronica; Miao, Hua-Quan et al. (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282:13326-33
Yang, Yang; MacLeod, Veronica; Dai, Yuemeng et al. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110:2041-8
Yang, Yang; Macleod, Veronica; Bendre, Manali et al. (2005) Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105:1303-9
Sanderson, Ralph D; Yang, Yang; Kelly, Thomas et al. (2005) Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem 96:897-905

Showing the most recent 10 out of 11 publications